Understand the source comparison
Kisspeptin's Mechanism: Reproductive Axis Regulation vs Metabolic Function
Kisspeptin-10 (the biologically active fragment) binds GPR54 receptors in the hypothalamus to stimulate GnRH neuron depolarization. GnRH then triggers anterior pituitary release of LH and FSH, which govern testosterone production in males and ovarian function
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Kisspeptin-10 (the biologically active fragment) binds GPR54 receptors in the hypothalamus to stimulate GnRH neuron depolarization. GnRH then triggers anterior pituitary release of LH and FSH, which govern testosterone production in males and ovarian function in females. This pathway is distinct from the incretin hormone system targeted by GLP-1 agonists like semaglutide. Kisspeptin has no direct effect on insulin secretion, gastric emptying, or appetite signaling.
- The half-life of kisspeptin-10 is approximately 27–30 minutes in vivo, significantly shorter than semaglutide (5–7 days) or tirzepatide (approximately 5 days). This short duration requires either multiple daily subcutaneous injections or extended-release formulations to sustain therapeutic GnRH pulsatility. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that continuous kisspeptin infusion restored LH pulse frequency in hypogonadotropic hypogonadism patients, but single-bolus administration produced only transient LH elevation lasting 90–120 minutes.
- Unlike growth hormone secretagogues (GHRP-2, ipamorelin, MK-677) that act on ghrelin receptors in the pituitary to stimulate GH release, kisspeptin has no direct growth-promoting effects. It influences anabolic hormone production indirectly by regulating testosterone synthesis. But only in contexts where hypogonadotropic function is the limiting factor. In eugonadal individuals, exogenous kisspeptin doesn't produce the muscle-building effects seen with direct GH secretagogues or selective androgen receptor modulators.
- Our experience working with peptide researchers shows a consistent pattern: misunderstanding receptor specificity leads to protocol failures. Kisspeptin won't replicate the metabolic outcomes of GLP-1 therapy, and GLP-1 agonists won't restore reproductive hormone pulsatility.